CD4 and neoplasm: Notwithstanding, as mentioned above, they may indirectly contribute to anti-tumour immunity by inducing the reverse process, i.e., by converting Treg into anti-tumour effector CD4+ T cells, as recently suggested in patients with metastatic melanoma, gastrointestinal, and ovarian cancer [391] (Table 2).